Community 365 Roundtable Meeting on Genomic Tumour Testing

The Community 365 Roundtable Meeting on the topic of Genomic Tumour Testing took place on Thursday 2 December from 14:00-16:30 CET

 

This meeting brought together leading policy-makers, politicians, oncology experts and patient advocates to discuss the implementation of Europe’s Beating Cancer Plan and Cancer Mission, as well as other EU policy developments relating to genomic tumour testing.

02 December 2021 14:00 - 16:30 CET

Virtual

 
  • View the Recording from the Roundtable meeting here

The Roundtable aimed at stimulating consensus and promoting better political understanding around current needs in order to achieve better access for cancer patients to genomic tumour testing across Europe.

There was a particular focus on the challenging misconceptions that have grown around the reality of genomic tumour testing. Patient testimonials were captured and discussion was promoted on policy challenges and recommendations to be considered, in the context of the attention given by Europe’s Beating Cancer Plan and the Horizon Europe’s EU Cancer Mission to the ongoing development of precision oncology and the monitoring, mitigation and resolution of cancer inequalities

The ‘human’ aspect of genomic tumour testing, and the needs of addressing associated workforce challenges and ensuring optimal patient information and shared decision-making was emphasised, while opportunities of better leveraging the power of data for successful implementation of genomic tumour testing across Europe was highlighted.

Programme


14:00-14:10 Introduction

Roundtable Co-Chairs:
  • Matti Aapro, President, European Cancer Organisation 
  • Mark Lawler, Board Member, European Cancer Organisation, and Chair in Translational Genomics, Queen’s University Belfast 
14:10-14:25 A Guide to Genomic Tumour Testing

  • Richard Price, Head of Policy, European Cancer Organisation
In conversation with:
  • Peter Schirmacher, President-Elect, European Society of Pathology (ESP)
14:25-15:00 The Advent of Tumour-Agnostic Therapies and their Impact on the Need for Genomic Tumour Testing 

Session Co-Chairs:
  • Gabriela Möslein, Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP)
  • Amy Van Buskirk, Global Product Strategy Oncology Head LASR (Lung, Agnostic, Skin & Rare Cancers), Roche
With contributions from:
  • Fatima Carneiro, Past-President, European Society of Pathology; Professor of Pathology and Director of the Unit of Pathology and Oncology, Medical Faculty of the University of Porto, Portugal; and Head of Department of Anatomic Pathology, Centro Hospitalar São João, Porto, Portugal
  • Fernando López-Ríos, Pathologist, "12 de Octubre" University Hospital, Madrid
  • Natacha Bolaños, Member, Patient Advisory Committee, European Cancer Organisation, and Global Alliances Manager & Regional Manager, Lymphoma Coalition Europe
15:00-15:35 Latest Evidence and Research Needs on Benefits and Costs of Genomic Tumour Testing

Session Co-Chairs:
  • Mark Lawler, Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen’s University Belfast
  • Brian Cuffel, Vice-President and Head of Market Access Oncology, Bayer
With contributions from:
  • Giancarlo Pruneri, Head, Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Full Professor of Pathology, University of Milan, School of Medicine; and President, Euro-Asian Mastology Association (EURAMA)
  • Bettina Ryll, Member, EU Cancer Mission Board, and Founder, Melanoma Patient Network Europe
15:35-16:10 Discrepancies in National Processes and Policies on Next Generation Sequencing 

Session Co-Chairs
  • Matti Aapro, President, European Cancer Organisation
  • John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca
With contributions from:
  • Nicola Normanno, President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society
  • Frédérique Penault-Llorca, Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER)
  • Piarella Peralta, Patient Advocate, Inspire2Live
16:10-16:25 Where Next? The Policy Context

Reflecting on discussions held on key challenge areas for genomic tumour testing held within the Roundtable's thematic sessions, contributions were invited by key participating experts, stakeholders and policymakers.

  • Richard Price, Head of Policy, European Cancer Organisation
16:25-16:30 Concluding Remarks

Roundtable Co-Chairs:
  • Matti Aapro, President, European Cancer Organisation 
  • Mark Lawler, Board Member, European Cancer Organisation, and Chair in Translational Genomics, Queen’s University Belfast 

 

Speakers

  • Matti Aapro President, European Cancer Organisation
  • Mark Lawler Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen's University Belfast (QUB)
  • Peter Schirmacher President-Elect, European Society of Pathology (ESP)
  • Gabriela Möslein Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP)
  • Nicola Normanno President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society
  • Frédérique Penault-Llorca Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER)

Speakers

  • Matti Aapro President, European Cancer Organisation
  • Mark Lawler Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen's University Belfast (QUB)
  • Peter Schirmacher President-Elect, European Society of Pathology (ESP)
  • Gabriela Möslein Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP)
  • Nicola Normanno President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society
  • Frédérique Penault-Llorca Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER)
  • Matti Aapro President, European Cancer Organisation Read Bio
  • Mark Lawler Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen's University Belfast (QUB) Read Bio
  • Peter Schirmacher President-Elect, European Society of Pathology (ESP) Read Bio
  • Gabriela Möslein Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP) Read Bio
  • Nicola Normanno President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society Read Bio
  • Frédérique Penault-Llorca Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER) Read Bio
  • Fatima Carneiro Past-President, European Society Of Pathology; Professor of Pathology and Director of the Unit of Pathology and Oncology, Medical Faculty of the University of Porto; and Head of Department of Anatomic Pathology, Centro Hospitalar São João, Porto
  • Giancarlo Pruneri Head, Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Full Professor of Pathology, University of Milan, School of Medicine; and President, Euro-Asian Mastology Association (EURAMA) Read Bio
  • Fernando López-Ríos Pathologist, "12 de Octubre" University Hospital, Madrid Read Bio
  • Bettina Ryll Member, EU Cancer Mission Board, and Founder, Melanoma Patient Network Europe
  • Natacha Bolaños Member, Patient Advisory Committee, European Cancer Organisation, and Global Alliances Manager & Regional Manager, Lymphoma Coalition Europe Read Bio
  • Piarella Peralta Patient Advocate, Inspire2Live
  • Brian Cuffel Vice-President and Head of Market Access Oncology, Bayer Read Bio
  • John Longshore Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca Read Bio
  • Amy Van Buskirk Global Product Strategy Oncology Head LASR (Lung, Agnostic, Skin & Rare Cancers), Roche Read Bio
  • Richard Price Head of Policy, European Cancer Organisation

Speakers

  • Matti Aapro President, European Cancer Organisation
  • Mark Lawler Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen's University Belfast (QUB)
  • Peter Schirmacher President-Elect, European Society of Pathology (ESP)
  • Gabriela Möslein Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP)
  • Nicola Normanno President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society
  • Frédérique Penault-Llorca Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER)

Speakers

  • Matti Aapro President, European Cancer Organisation
  • Mark Lawler Board Member, European Cancer Organisation and Chair in Translational Genomics, Queen's University Belfast (QUB)
  • Peter Schirmacher President-Elect, European Society of Pathology (ESP)
  • Gabriela Möslein Chair, European Hereditary Tumour Group (EHTG), and Past-General-Secretary, European Society of Coloproctology (ESCP)
  • Nicola Normanno President, International Quality Network for Pathology (IQNPath); Chief of the Cell Biology and Biotherapy-Unit, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione ″G. Pascale″, Naples, Italy; and President-Elect, Italian Cancer Society
  • Frédérique Penault-Llorca Director-General, Jean Perrin Cancer Centre, Clermont-Ferrand, France, and Vice-President, Federation of French Cancer Centres (UNICANCER)